Karyopharm Therapeutics Inc. (NASDAQ: KPTI) Expects Full Year 2021 Revenue of $29.7 Million For XPOVIO

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) has announced interim Q4 and full-year 2021 net revenue forecasts for its first in class oral XPO1 inhibitor, XPOVIO, and outlined achievements of 2021 and 2022 objectives. 

XPOVIO revenue for Q4 is expected to be $29.7 million 

The company forecasts net product sales of XPOVIO to be around $29.7 million in the fourth quarter and around $98.3 million for the whole year 2021, based on interim unaudited financial data. 

CEO Richard Paulson said, “For 2022, we are focused on making significant advances across our pipeline, beginning with top-line results from the Phase 3 SIENDO study evaluating selinexor as a maintenance therapy following front-line chemotherapy in patients with advanced or metastatic endometrial cancer, which remain on track to be reported this quarter. Building on the strong revenue growth in the second half of 2021, we will continue to prioritize driving sales and the adoption of XPOVIO in multiple myeloma. I am extremely pleased with the continued progress of our pipeline in key additional indications of multiple myeloma, myelodysplastic syndromes and myelofibrosis and our ability to further expand our impact on patients globally with our recent partnership with Menarini.” 

Last year the company unveiled XPOVIO in the US, which is its second multiple myeloma line, and enhanced its commercial team leading to continued solid net product revenue in 2021. Also, the company generated convincing clinical data that support Selinexor’s efficacy, tolerability, and durability when combined with cleared agents like Pomalyst (pomalidomide), Velcade (bortezomib), or Kyprolis (carfilzomib) in patients that have been exposed to anti-CD38 monoclonal antibody therapy, where there is a significant unmet need for a new therapy line. 

Karyopharm to report SIENDO study results in Q1 2022

In 2022 the company is looking to leverage its commercial capabilities to boost XPOVIO sales in the US. Also, the company will report top-line results from the third phase SIENDO study evaluating Selinexor as an endometrial cancer maintenance therapy in Q1 2022. If the results are positive, Karyopharm will submit a supplemental New Drug Application for Selinexor in endometrial cancer in 1H 2022.